TABLE 3.
Characteristics of the study participants with day 28 parasitemia detected by microscopy or PCR
| Patient ID | Sex/age (yr) | Trial arm | Day 28 parasitemia (no. of parasites/μl blood) determined by: |
Day 28 sign(s) and/or symptom(s) reported | Day 28 CQ/DCQ level (ng/ml)a | Status of paired genotypesb | |
|---|---|---|---|---|---|---|---|
| Microscopy | PCR | ||||||
| 1/4 | Male/13 | 1 | Negative | 25 | None | 331.5 | Identicalc |
| 1/27 | Female/36 | 1 | Negative | 4 | None | 119.3 | Identicalc |
| 1/28 | Female/24 | 1 | Negative | 3 | None | 980.9 | Identicald |
| 1/55 | Female/10 | 1 | 83 | 22 | Malaise, anorexia, headache, and arthralgia | 108.5 | Identicalc |
| 1/58 | Female/12 | 1 | Negative | 99 | None | 97.7 | Identicalc |
| 1/66 | Male/13 | 1 | Negative | 167 | None | 387.9 | Identicalc |
| 1/74 | Female/14 | 1 | 2,942 | 1,573 | Chills, headache, myalgia, arthralgia, and low-back pain | 140.9 | Identicalc |
| 2/70 | Male/12 | 2 | Negative | 3 | None | 78.3 | Identicalc |
a
Therapeutic whole-blood levels (>100 ng/ml) are underlined.
b
Comparison of multilocus genotypes obtained with six microsatellite loci from parasite samples collected from the same subject at day 0 (pretreatment) and day 28 (day of recurrence).
c
Identical predominant or only alleles at all 6 microsatellite loci that were successfully amplified from paired samples.
d
Identical predominant alleles or only alleles at 5 microsatellite loci; amplification of one marker from the day 28 sample failed.